
Hummingbird Bioscience CEO Piers Ingram (L) and Synaffix CEO Peter van de Sande
Hummingbird and Synaffix agree to antibody-drug conjugate deal worth up to $150M
The Dutch biotech Synaffix has been active on the deal front for the past few years. And it’s not showing signs of stopping, hitting the ground running in 2023 by inking a deal with Singapore’s Hummingbird Bioscience.
In an announcement Monday, Hummingbird and the antibody-drug conjugate biotech said they will enter into a licensing agreement, opening the door for Hummingbird to develop an ADC program using Synaffix’s technology.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters